CONCEPTUAL SUMMARY
Risk Factors: Age, female gender, personal history of breast cancer or benign breast disease, early thoracic radiation, family history (first-degree relative < 50 years or ≥ 2 relatives at any age), obesity, alcohol use, BRCA1/2 and other genetic mutations (CHEK2, ATM, PALB2), breast density, early menarche (≤ 12 years), late natural menopause (≥ 55 years), age ≥ 30 at first birth or nulliparity, exogenous estrogen exposure. Early oophorectomy before age 50 DECREASES risk. Race and premenopausal status are NOT independent risk factors.
Risk Reduction Strategies:
- Prophylactic bilateral mastectomy provides the GREATEST risk reduction in BRCA1/2 carriers.
- Risk-reducing salpingo-oophorectomy provides the next greatest reduction.
- Chemoprevention options:
- Tamoxifen (for premenopausal OR postmenopausal women ≥ 35 years, reduces ER+ cancer ~50%);
- raloxifene (postmenopausal only, similar to tamoxifen for invasive cancer, less effective for DCIS, less endometrial risk);
- aromatase inhibitors — exemestane and anastrozole (postmenopausal only, reduce cancer ~50–65%).
- Goserelin (LHRH agonist) is NOT a risk reduction strategy. Aromatase inhibitors are ONLY for postmenopausal women.
Screening: Women with a first-degree relative diagnosed with breast cancer should begin mammography 10 years before the youngest relative's age at diagnosis (but generally not before age 30–40). A mother diagnosed at age 49 → daughter should start mammography at age 39. Clinical breast exam (CBE) and breast MRI are added for high-risk women (lifetime risk > 20%).
Oncotype DX Recurrence Score:
- RS < 26 in women > 50 or postmenopausal: endocrine therapy alone (no chemotherapy benefit).
- RS ≥ 26 (or RS 16–25 in women ≤ 50): chemotherapy recommended followed by endocrine therapy.
- RS < 26 in women aged ≤ 50 with RS 16–25: chemotherapy may be considered.
Prognostic Factors:
- Good prognosis: ER+/PR+, HER2−, low grade, small tumor (< 2 cm), node-negative, low Ki-67, Luminal A subtype.
- Poor prognosis: ER−/PR−/HER2−, high grade (3), large tumor, node-positive, high Ki-67, TNBC, lymphovascular invasion (LVI), stage IV at diagnosis.
Adjuvant Endocrine Therapy Rules:
- Premenopausal:
- Tamoxifen 20 mg daily × 5–10 years.
- Aromatase inhibitors (AIs) can ONLY be used in premenopausal women if combined with ovarian suppression (OAS). OAS + AI or OAS + tamoxifen: 5 years only for this combination.
- Postmenopausal:
- AIs preferred (letrozole, anastrozole, exemestane × 5–10 years).
- Tamoxifen is reserved for postmenopausal women with AI contraindication/intolerance.
- Goserelin (OAS) is NOT needed for postmenopausal women.
- The combination of tamoxifen + fulvestrant is NOT recommended. Major tamoxifen toxicities: endometrial cancer, VTE (PE, DVT), cataracts, ischemic heart disease (10-year therapy), and bone loss (premenopausal). Avoid strong CYP2D6 inhibitors (paroxetine, fluoxetine) with tamoxifen — use venlafaxine or citalopram for hot flashes.
- Trastuzumab should NEVER be given concurrently with anthracyclines (significantly increased cardiotoxicity).
- Neoadjuvant HER2+ regimen: TCH+P (docetaxel + carboplatin + trastuzumab + pertuzumab) OR AC → THP.
- After neoadjuvant therapy:
- residual disease → switch to T-DM1 × 14 cycles (KATHERINE trial).
- No residual disease → continue trastuzumab ± pertuzumab to complete 1 year.
- Neratinib = extended adjuvant after 1 year of trastuzumab; NOT for primary adjuvant. LVEF monitoring: baseline + every 12 weeks during neoadjuvant pertuzumab; every 3 months during trastuzumab therapy. Hold trastuzumab/pertuzumab if LVEF < 50% AND absolute decrease ≥ 10 percentage points from baseline.
- Metastatic HER2+:
- first-line = trastuzumab + pertuzumab + taxane.
- Second-line = fam-trastuzumab deruxtecan (T-DXd, DESTINY-Breast03 showed superiority over T-DM1).
T-DM1 vs T-DXd:
- T-DM1 payload = emtansine (microtubule inhibitor). Key toxicities: thrombocytopenia, peripheral neuropathy, and elevated LFTs.
- T-DXd payload = deruxtecan (topoisomerase I inhibitor). Key toxicity: BLACK BOX WARNING for interstitial lung disease (ILD)/pneumonitis (potentially fatal). T-DXd is also approved for HER2-low metastatic breast cancer (IHC 1+ or IHC 2+/ISH−) — T-DM1 is NOT indicated for HER2-low.
Triple-Negative Breast Cancer (TNBC)
- No endocrine or HER2-targeted options.
- Neoadjuvant TNBC: pembrolizumab + carboplatin + paclitaxel → pembrolizumab + AC (KEYNOTE-522) — improves event-free survival.
- Adjuvant TNBC: if residual disease after neoadjuvant chemo → capecitabine × 6–8 cycles (CREATE-X trial) OR olaparib × 1 year if germline BRCA1/2 mutation (OlympiA trial).
- Metastatic TNBC: PD-L1+ (CPS ≥ 10): pembrolizumab + chemo (KEYNOTE-355). Germline BRCA1/2+: olaparib or talazoparib (PARP inhibitors preferred over taxane). Single-agent carboplatin is NOT recommended in the adjuvant setting.
Metastatic HR+/HER2−:
- First-line: CDK4/6 inhibitor (palbociclib, ribociclib, abemaciclib) + AI or fulvestrant. Premenopausal patients require OAS in addition.
- After CDK4/6 inhibitor progression:
- PIK3CA mutation → alpelisib + fulvestrant (SOLAR-1).
- ESR1 mutation → elacestrant monotherapy (EMERALD trial).
- No actionable mutation → everolimus + exemestane (BOLERO-2, after nonsteroidal AI progression).
- AKT1/PTEN/PIK3CA mutations → capivasertib + fulvestrant. Alpelisib is ONLY approved with fulvestrant — NOT with anastrozole or tamoxifen. Ribociclib + tamoxifen: NOT recommended (QTc prolongation risk).
Bone Health: For bone metastases: zoledronic acid 4 mg IV every 3–4 weeks OR denosumab 120 mg SQ every 4 weeks. Denosumab 60 mg SQ every 6 months = for osteopenia/osteoporosis (NOT for bone metastases). Pamidronate should be given every 3–4 weeks (NOT every 6 months). For AI-induced bone loss: zoledronic acid every 6 months or annually; denosumab every 6 months; DXA every 2 years. Monitor calcium, creatinine, and electrolytes with bisphosphonates.
Chemotherapy Rules: Paclitaxel single-agent is NOT recommended in the adjuvant setting. Carboplatin single-agent is NOT recommended in the adjuvant setting. CMF is an option but NOT a preferred NCCN adjuvant regimen. Dose-dense AC → paclitaxel and TC × 4 are preferred adjuvant regimens for TNBC. G-CSF (filgrastim) primary prophylaxis is recommended when febrile neutropenia risk is > 20% or for dose-dense regimens.
PRACTICE QUESTIONS — BREAST CANCER
TS is a 36-year-old premenopausal white female with LCIS and a significant family history (mother, maternal grandmother, and maternal aunt all diagnosed with breast cancer before age 60). She had her first child at age 31. First menarche at age 12. What are TS's risk factors for developing invasive ductal carcinoma?
A. Premenopausal status, family history, race, and LCIS
B. LCIS, family history, early age of menarche, age > 30 at birth of first child
C. Family history, race, early age of menarche, age > 30 at birth of first child
D. Premenopausal status, age, LCIS, and < 3 pregnancies
Explanation: LCIS is an established risk factor for invasive breast cancer (approximately 8–10× increased risk). Strong family history (multiple first-degree relatives diagnosed before age 60) is a major risk factor. Early menarche (≤ 12 years) increases lifetime estrogen exposure, elevating risk. Age > 30 at first birth (or nulliparity) is a hormonal risk factor. Premenopausal status (option A, D) is NOT an independent risk factor for breast cancer. Race (options A, C) is NOT a risk factor for breast cancer development. Age alone and number of pregnancies (option D) are not the correct risk characterization for TS.
[/expand]TS has a > 20% lifetime risk of breast cancer by the Tyrer-Cuzick model. She declined genetic testing. She is premenopausal. What is an appropriate pharmacologic risk reduction strategy for TS according to NCCN Guidelines?
A. Tamoxifen
B. Goserelin
C. Anastrozole
D. Raloxifene
Explanation:
- For premenopausal women aged ≥ 35 with elevated breast cancer risk, tamoxifen is the appropriate chemoprevention option. It reduces the risk of ER+ breast cancer by approximately 50%.
- Goserelin (option B) is an LHRH agonist — it is NOT recommended as a risk reduction strategy.
- Anastrozole (option C) is an aromatase inhibitor — AIs are only indicated for postmenopausal women; they cannot be used as single-agent chemoprevention in premenopausal women.
- Raloxifene (option D) is only indicated for postmenopausal women. If TS were postmenopausal, her chemoprevention options would include tamoxifen, raloxifene, or an aromatase inhibitor.
A 21-year-old female whose mother was diagnosed with breast cancer at age 49 asks about breast cancer screening recommendations. What would you recommend?
A. Start CBE and mammography as soon as possible, then yearly
B. Start CBE, mammography, and MRI as soon as possible, then yearly
C. Start CBE and mammography when you are 39 years old, then yearly
D. Start CBE, mammography, and MRI when you are 39 years old, then yearly
Explanation: For women with a first-degree relative diagnosed with breast cancer, screening mammography should begin 10 years before the relative's age at diagnosis — but generally not before age 30–40. Mother diagnosed at age 49 → daughter should begin at age 39. At age 21, mammography and breast MRI are not recommended without a known BRCA mutation or very high-risk genetic predisposition. Clinical breast awareness/CBE may be encouraged earlier. Annual breast MRI (option D) would be added only if she were determined to be high-risk (> 20% lifetime risk) by a formal risk model or confirmed genetic mutation — which has not been established in this case.
[/expand]JH is a 39-year-old premenopausal woman with stage IIA (pT2, pN0, M0), ER+/PR+/HER2− invasive ductal carcinoma, nuclear grade 1. Oncotype DX recurrence score = 26. She underwent a lumpectomy with negative axillary nodes. What is the most appropriate adjuvant therapy for JH according to NCCN Guidelines?
A. Anastrozole
B. Docetaxel and cyclophosphamide (TC) followed by anastrozole
C. Tamoxifen
D. Docetaxel and cyclophosphamide (TC) followed by tamoxifen
Explanation: JH has a high recurrence score (RS = 26) — chemotherapy is indicated based on the TAILORx trial (RS ≥ 26 benefits from chemotherapy). TC or AC → paclitaxel are appropriate chemotherapy options. Following chemotherapy, tamoxifen is the correct endocrine therapy because JH is premenopausal — AIs cannot be used as single-agent endocrine therapy in premenopausal women. Anastrozole alone (option A) is incorrect — JH needs chemotherapy AND anastrozole is not appropriate for premenopausal patients without OAS. Option B pairs TC with anastrozole — incorrect because anastrozole requires OAS in premenopausal women. Tamoxifen alone (option C) is incorrect because JH's RS = 26 mandates chemotherapy.
[/expand]If JH were postmenopausal, what would be the most appropriate adjuvant endocrine therapy following her course of chemotherapy?
A. Anastrozole × 5 years
B. Goserelin + anastrozole × 10 years
C. Tamoxifen × 10 years
D. Goserelin + tamoxifen × 5 years
Explanation: For postmenopausal patients, aromatase inhibitors (anastrozole, letrozole, exemestane) are the preferred adjuvant endocrine therapy — NCCN recommends AI for 5–10 years. Tamoxifen for 5–10 years is an alternative only if the patient has a contraindication or intolerance to AIs. Options B and D containing goserelin are incorrect — goserelin (OAS) is only needed for premenopausal women to achieve estrogen suppression; postmenopausal women have naturally low estrogen and do not require OAS. The combination of OAS + AI or OAS + tamoxifen is only recommended for premenopausal patients and only for 5 years.
[/expand]CH is a 46-year-old postmenopausal woman with stage IIA (pT2, pN0, M0), ER+/HER2− invasive ductal carcinoma, nuclear grade 1. Oncotype DX recurrence score = 11. She underwent a lumpectomy with negative axillary nodes.
What is the most appropriate adjuvant therapy for CH according to NCCN Guidelines?
A. Anastrozole
B. Docetaxel and cyclophosphamide (TC) followed by anastrozole
C. Tamoxifen
D. Docetaxel and cyclophosphamide (TC) followed by tamoxifen
Explanation: CH has a LOW recurrence score (RS = 11) — based on the TAILORx trial, chemotherapy is NOT routinely recommended for patients with RS < 26, and endocrine therapy alone is sufficient. For postmenopausal patients, aromatase inhibitors (anastrozole) are preferred over tamoxifen. Tamoxifen alone (option C) is incorrect — an AI is preferred for postmenopausal patients; tamoxifen is reserved for those with AI contraindication/intolerance. Options B and D are incorrect — chemotherapy is not indicated for a RS of 11. Chemotherapy can be considered for patients aged ≤ 50 with RS 16–25, but CH is 46 with RS = 11.
[/expand]If CH were premenopausal, what would be the most appropriate adjuvant endocrine therapy?
A. Anastrozole × 5 years
B. Goserelin + anastrozole × 10 years
C. Tamoxifen × 10 years
D. Exemestane × 5 years
Explanation: For premenopausal patients with lower-risk early-stage breast cancer, tamoxifen 20 mg daily is the standard endocrine therapy — recommended for 5–10 years. ASCO guidelines state women should receive an additional 5 years of tamoxifen if they remain premenopausal after the initial 5 years (total 10 years). The combination OAS + AI or OAS + tamoxifen should be considered for higher-risk patients (lymph node involvement, high grade, young age) — not for CH who is lower risk. Single-agent AIs (options A and D) cannot be used in premenopausal women without OAS. Option B (goserelin + anastrozole × 10 years) is incorrect — this combination is only recommended for 5 years (not 10).
[/expand]CW is a postmenopausal woman with ER+/PR+/HER2− breast cancer, staged T2 N2 M0 (3 cm primary tumor, 4 positive lymph nodes). She received neoadjuvant chemotherapy followed by breast-conserving surgery and radiation. She has no major comorbidities and desires aggressive treatment. What is the most appropriate adjuvant endocrine therapy for CW?
A. Anastrozole + leuprolide
B. Anastrozole + abemaciclib
C. Anastrozole
D. Tamoxifen
Explanation: CW has 4 positive lymph nodes — this meets the high-risk criteria for addition of abemaciclib (CDK4/6 inhibitor) to endocrine therapy. Per ASCO and NCCN guidelines based on the MonarchE trial, abemaciclib × 2 years + endocrine therapy is recommended for patients with ≥ 4 positive lymph nodes OR 1–3 positive nodes plus at least one additional high-risk feature. Anastrozole + leuprolide (option A) — leuprolide is OAS, only needed for premenopausal patients; CW is postmenopausal. Anastrozole alone (option C) — appropriate if CW declines or cannot tolerate abemaciclib, but abemaciclib is preferred given her high-risk status and desire for aggressive treatment. Tamoxifen (option D) — only appropriate for postmenopausal patients with AI contraindication/intolerance.
[/expand]VT is a 58-year-old postmenopausal woman with stage IIIA (T2N2M0) ER−/PR−/HER2− TNBC with germline BRCA1 mutation. She received neoadjuvant AC × 4 cycles → weekly paclitaxel × 12 cycles, followed by breast-conserving surgery. She has residual disease at surgery. In addition to radiation, which adjuvant treatment is most appropriate for VT?
A. Ado-trastuzumab emtansine
B. Docetaxel + cyclophosphamide
C. Paclitaxel + carboplatin
D. Olaparib
Explanation: VT has germline BRCA1 mutation + TNBC with residual disease after neoadjuvant chemotherapy — these are the criteria for adjuvant olaparib × 1 year per the OlympiA trial, which demonstrated improved invasive disease-free survival. T-DM1 (option A) is only for HER2+ residual disease — VT is HER2−. Docetaxel + cyclophosphamide (option B) is an adjuvant option for patients who have NOT received neoadjuvant chemotherapy — VT already completed full neoadjuvant treatment. Paclitaxel + carboplatin (option C) is not recommended in the adjuvant setting.
[/expand]VT is a 58-year-old postmenopausal woman with stage IIIA TNBC (no BRCA mutation noted in this scenario). She received neoadjuvant AC × 4 → weekly paclitaxel × 12, followed by breast-conserving surgery with residual disease at surgery. In addition to radiation, which adjuvant treatment is most appropriate for VT?
A. Ado-trastuzumab emtansine
B. Docetaxel + cyclophosphamide
C. Paclitaxel + carboplatin
D. Capecitabine
Explanation: For patients with HER2-negative breast cancer who have residual invasive disease at surgery after neoadjuvant anthracycline and taxane-based chemotherapy, capecitabine × 6–8 cycles is recommended based on the CREATE-X trial, which demonstrated improved disease-free survival. T-DM1 (option A) is only for HER2+ residual disease. Docetaxel + cyclophosphamide (option B) is for adjuvant use in patients who have not received neoadjuvant chemotherapy. Paclitaxel + carboplatin (option C) is not recommended in the adjuvant setting.
[/expand]HF is a 60-year-old woman with stage IIIB (T4, N2, M0), ER+/HER2 IHC 3+ breast cancer who prefers lumpectomy over mastectomy. She must receive neoadjuvant chemotherapy to downstage her tumor. What neoadjuvant regimen would be most appropriate?
A. AC + trastuzumab × 4 cycles
B. Docetaxel + trastuzumab + pertuzumab × 6 cycles
C. TCH + pertuzumab × 6 cycles
D. AC × 4 cycles → weekly paclitaxel × 12
Explanation: For HER2+ breast cancer requiring neoadjuvant therapy, docetaxel + carboplatin + trastuzumab + pertuzumab (TCHP × 6 cycles) is a guideline-recommended option based on the TRYPHAENA study. Dual HER2 blockade (trastuzumab + pertuzumab) maximizes pathologic complete response (pCR). AC + trastuzumab (option A) is incorrect — trastuzumab must NEVER be given concurrently with anthracyclines (significantly increased cardiotoxicity). Docetaxel + trastuzumab + pertuzumab without chemotherapy backbone (option B) — this combination without a taxane and carboplatin backbone is listed as a metastatic option, not standard neoadjuvant. AC alone → paclitaxel (option D) omits HER2-directed therapy entirely — unacceptable for HER2+ disease.
[/expand]HF is planned to receive TCHP × 6 cycles for HER2+ stage IIIB breast cancer. According to pertuzumab's prescribing information, what is the appropriate frequency for monitoring HF's LVEF during neoadjuvant therapy following baseline assessment?
A. Every 12 weeks
B. Every 6 months
C. Every 6 weeks
D. Every 2 months
Explanation: Per pertuzumab's prescribing information, LVEF monitoring via ECHO or MUGA scan is required at baseline and every 12 weeks during neoadjuvant treatment (at least once during neoadjuvant therapy). This schedule detects the reversible cardiomyopathy associated with HER2-targeted therapy. Every 6 months (option B) is far too infrequent during active treatment. Every 6 weeks (option C) and every 2 months (option D) are not the standard monitoring intervals specified in the prescribing information.
[/expand]After completing neoadjuvant TCHP × 6 cycles, HF undergoes lumpectomy and is found to have RESIDUAL DISEASE at surgery. Which is the most appropriate adjuvant HER2-directed regimen for HF?
A. Pertuzumab
B. Ado-trastuzumab emtansine (T-DM1)
C. Trastuzumab + pertuzumab
D. Neratinib
Explanation:
- Based on the KATHERINE trial, T-DM1 × 14 cycles is the standard for patients with HER2+ early breast cancer who have residual invasive disease at surgery after neoadjuvant trastuzumab-based therapy — it significantly improves invasive disease-free survival compared to trastuzumab alone.
- Single-agent pertuzumab (option A) is not recommended — it should only be used in combination with trastuzumab.
- Trastuzumab + pertuzumab (option C) would be appropriate if HF had NO residual disease — but she has residual disease, making T-DM1 the preferred choice.
- Neratinib (option D) is only indicated as extended adjuvant therapy AFTER completing 1 year of trastuzumab — not as primary adjuvant in place of T-DM1.
After completing neoadjuvant TCHP × 6 cycles, HF undergoes lumpectomy and is found to have NO RESIDUAL DISEASE at surgery. Which is the most appropriate adjuvant HER2-directed regimen for HF?
A. Pertuzumab
B. Ado-trastuzumab emtansine
C. Trastuzumab + pertuzumab
D. Neratinib
Explanation: When there is NO residual disease after neoadjuvant trastuzumab + pertuzumab-based therapy, guidelines recommend continuing trastuzumab ± pertuzumab in the adjuvant setting to complete 1 year of total HER2-targeted therapy. Since HF received both trastuzumab and pertuzumab neoadjuvantly, it is reasonable to continue both agents. T-DM1 (option B) is specifically for patients WITH residual disease — HF has no residual disease. Single-agent pertuzumab (option A) is not appropriate without trastuzumab. Neratinib (option D) is extended adjuvant therapy (year 2) after completing 1 year of trastuzumab — not the primary adjuvant choice here.
[/expand]While receiving adjuvant trastuzumab and pertuzumab, HF's LVEF decreased from a baseline of 60% to 49% (absolute decrease of 11 percentage points). What is the most appropriate action at this time?
A. Continue trastuzumab and pertuzumab
B. Hold trastuzumab and pertuzumab
C. Restart trastuzumab but discontinue pertuzumab
D. Restart pertuzumab but discontinue trastuzumab
Explanation: Trastuzumab and pertuzumab should be HELD when LVEF drops below 50% with an absolute decrease of ≥ 10 percentage points from baseline. HF's LVEF is 49% (< 50%) with an absolute decrease of 11 points (≥ 10 points) — both criteria are met. After holding, LVEF should be reassessed at 4-week intervals. If LVEF recovers, therapy may be restarted. Continuing therapy (option A) or selectively restarting only one agent (options C and D) are incorrect — both agents should be held simultaneously based on the shared cardiotoxicity concern.
[/expand]MZ is a 37-year-old premenopausal woman with stage IIB (T2,N1,M0), ER−/PR−/HER2− TNBC, nuclear grade 3, Ki-67 50%, germline BRCA2 mutation. She is planned for neoadjuvant chemotherapy followed by lumpectomy. Which neoadjuvant regimen would be most appropriate according to NCCN Guidelines?
- Cyclophosphamide + methotrexate + fluorouracil (CMF)
- Pembrolizumab + carboplatin + paclitaxel → pembrolizumab + doxorubicin + cyclophosphamide (AC)
- Dose-dense doxorubicin + cyclophosphamide (AC) → paclitaxel
- Doxorubicin + cyclophosphamide (AC) → docetaxel
Explanation: Based on the KEYNOTE-522 trial, pembrolizumab + chemotherapy (carboplatin + paclitaxel → AC) significantly improved event-free survival compared to chemotherapy alone in TNBC. This is now a Category 1 NCCN preferred neoadjuvant regimen for TNBC. After surgery, adjuvant pembrolizumab × 9 cycles is continued. CMF (option A) is an adjuvant option but not a preferred NCCN regimen. Options C and D (dose-dense AC → paclitaxel and AC → docetaxel) omit immunotherapy — these could be considered if pembrolizumab is contraindicated or not tolerated, but are not preferred given the EFS benefit of pembrolizumab in TNBC.
[/expand]BZ is a 50-year-old postmenopausal woman with metastatic ER=0%/PR=0%/HER2−/PD-L1 negative breast cancer with liver and lung metastases causing jaundice and dyspnea. She has germline BRCA1/2 positive status. Which of the following first-line regimens is most appropriate for BZ?
A. Rucaparib
B. Talazoparib
C. Gemcitabine
D. Docetaxel
Explanation: BZ has germline BRCA1/2-mutated, HER2-negative metastatic breast cancer. PARP inhibitors (olaparib or talazoparib) are preferred first-line treatment options for this population — the EMBRACA trial (talazoparib) and OlympiAD trial (olaparib) both demonstrated improved median PFS and response rates compared to chemotherapy. Rucaparib (option A) has not been adequately studied in breast cancer and is not approved for this indication. Gemcitabine and docetaxel (options C and D) are chemotherapy options but are less preferred given the superior outcomes demonstrated with PARP inhibitors in germline BRCA-mutated metastatic breast cancer.
[/expand]GS is a 62-year-old with HER2+ metastatic breast cancer. She received adjuvant AC × 4 → paclitaxel + trastuzumab × 12 weeks → trastuzumab to complete 1 year. She now presents with bone and lung metastases on re-staging. Which regimen is most appropriate for GS at this time?
A. Trastuzumab alone
B. Pertuzumab + docetaxel
C. Trastuzumab + lapatinib
D. Trastuzumab + pertuzumab + docetaxel
Explanation: For HR−/HER2+ metastatic breast cancer, the Category 1 first-line standard is docetaxel + trastuzumab + pertuzumab (THP) — supported by the CLEOPATRA trial showing improved OS. Chemotherapy must be added to anti-HER2 therapy for HR-negative/HER2+ metastatic disease. Trastuzumab alone (option A) is insufficient — dual HER2 blockade with chemotherapy is required. Pertuzumab alone with docetaxel (option B) is incorrect — pertuzumab must always be combined with trastuzumab. Trastuzumab + lapatinib (option C) is a later-line combination that does not include chemotherapy — inappropriate for HR−/HER2+ metastatic disease as first-line.
[/expand]GS received THP × 8 months and then developed new liver metastases. Which regimen is most appropriate for GS at this time?
A. Capecitabine + lapatinib
B. Ado-trastuzumab emtansine (T-DM1)
C. Trastuzumab + lapatinib
D. Lapatinib monotherapy
Explanation: After first-line THP progression, the next preferred option is fam-trastuzumab deruxtecan (T-DXd) based on DESTINY-Breast03 showing superiority over T-DM1. However, among the choices provided, T-DM1 is the most appropriate option — it has shown improved PFS and OS over capecitabine + lapatinib (EMILIA trial). T-DM1 would be preferred over capecitabine + lapatinib given the EMILIA data. Trastuzumab + lapatinib (option C) requires cytotoxic chemotherapy in patients with visceral (liver) metastases — lapatinib-based combinations without chemo are not preferred. Lapatinib monotherapy (option D) is never recommended as single-agent therapy.
[/expand]GS is a 62-year-old with HER2+ metastatic breast cancer who received THP × 6 cycles → trastuzumab + pertuzumab maintenance for 6 months → now has progressive lung metastases. Which second-line regimen is most appropriate?
A. Neratinib + capecitabine
B. Fam-trastuzumab deruxtecan (T-DXd)
C. Trastuzumab + lapatinib
D. Ado-trastuzumab emtansine (T-DM1)
Explanation: Based on the DESTINY-Breast03 trial, T-DXd (fam-trastuzumab deruxtecan) is the preferred second-line therapy for HER2+ metastatic breast cancer after first-line THP, demonstrating superior PFS and OS compared to T-DM1. NCCN and ASCO guidelines designate T-DXd as the preferred second-line agent. Neratinib + capecitabine (option A) and trastuzumab + lapatinib (option C) are third-line or later regimens. T-DM1 (option D) was the previous standard second-line agent but has been superseded by T-DXd based on DESTINY-Breast03.
[/expand]CG is a 67-year-old postmenopausal woman with newly diagnosed metastatic HR+/HER2− breast cancer (ER 40%, PR 10%, HER2 2+ IHC/negative ISH) with bone metastases. What first-line treatment is most appropriate for CG?
A. Ribociclib + letrozole
B. Elacestrant
C. Alpelisib + letrozole
D. Fulvestrant
Answer: A. Ribociclib + letrozole
Explanation: CG has HR+/HER2− metastatic breast cancer — the standard first-line approach is a CDK4/6 inhibitor + aromatase inhibitor. Ribociclib + letrozole (or palbociclib, abemaciclib + AI/fulvestrant) is a Category 1 preferred regimen for first-line HR+/HER2− metastatic breast cancer. Elacestrant (option B) is only indicated in the second-line and beyond for patients with ESR1 mutations after prior endocrine therapy — not first-line. Alpelisib + letrozole (option C) is incorrect — alpelisib is approved only with FULVESTRANT (not anastrozole or letrozole) for PIK3CA-mutated disease after prior endocrine therapy progression. Fulvestrant monotherapy (option D) is not the preferred first-line strategy when CDK4/6 inhibitors are available.
[/expand]CG progressed after 2 years of ribociclib + letrozole. Additional biomarker testing reveals an ESR1 mutation but no PIK3CA mutation or germline BRCA mutation. What second-line treatment is most appropriate for CG?
A. Fulvestrant
B. Alpelisib + fulvestrant
C. Olaparib + elacestrant
D. Elacestrant
Explanation: CG has an ESR1 mutation and has progressed on prior CDK4/6 inhibitor + endocrine therapy — the EMERALD trial established elacestrant monotherapy as the standard for patients with ESR1-mutated HR+/HER2− metastatic breast cancer who have progressed on at least one line of endocrine therapy, including a CDK4/6 inhibitor. Elacestrant demonstrated improved PFS over fulvestrant particularly in ESR1-mutated patients. Fulvestrant (option A) is inferior to elacestrant in this ESR1-mutated setting. Alpelisib + fulvestrant (option B) is only appropriate for PIK3CA-mutated disease — CG has no PIK3CA mutation. Olaparib + elacestrant (option C) is not a recommended combination — olaparib requires BRCA mutation, which CG does not have.
[/expand]DS is a 45-year-old premenopausal woman with metastatic HR+/HER2− breast cancer (PIK3CA mutation) with bone and pelvic metastases. What first-line treatment is most appropriate for DS?
A. Alpelisib + anastrozole
B. Alpelisib + anastrozole + goserelin
C. Abemaciclib + letrozole
D. Abemaciclib + letrozole + goserelin
Explanation: DS is premenopausal with HR+/HER2− metastatic breast cancer — the first-line standard is CDK4/6 inhibitor + AI + OAS (goserelin). Since she is premenopausal, OAS must be added to eliminate ovarian estrogen production before AI therapy can be effective. Although DS has a PIK3CA mutation, alpelisib is reserved for the SECOND-LINE and beyond after prior endocrine therapy progression (options A and B are incorrect). Alpelisib is also only approved in combination with fulvestrant — NOT anastrozole. Option C (abemaciclib + letrozole without OAS) is incorrect because premenopausal patients require OAS when receiving AI-based therapy.
[/expand]DS is a 60-year-old postmenopausal woman with metastatic ER+/PR+/HER2− breast cancer with bone and lung metastases. What first-line treatment is most appropriate for DS?
A. Palbociclib + letrozole
B. Everolimus + exemestane
C. Goserelin + tamoxifen
D. Capecitabine + trastuzumab
Explanation: Palbociclib + letrozole (or any CDK4/6 inhibitor + AI) is the Category 1 preferred first-line regimen for postmenopausal HR+/HER2− metastatic breast cancer. DS has only bone and lung metastases without symptomatic visceral crisis — endocrine-based therapy with CDK4/6 inhibitor is preferred over chemotherapy. Everolimus + exemestane (option B) is indicated after failure of a nonsteroidal AI — not first-line. Goserelin (option C) is only for premenopausal patients. Trastuzumab (option D) is only for HER2+ disease — DS is HER2−.
[/expand]DS progressed after 15 months of palbociclib + letrozole. Additional biomarker testing reveals no actionable mutations. Which is the most appropriate second-line treatment for DS?
A. Abemaciclib + anastrozole
B. Everolimus + exemestane
C. Alpelisib + fulvestrant
D. Ribociclib + tamoxifen
Explanation: After progression on a nonsteroidal AI (letrozole) + CDK4/6 inhibitor in the absence of actionable mutations (no PIK3CA, no ESR1, no BRCA), everolimus + exemestane is the recommended next option based on the BOLERO-2 trial. Switching to another CDK4/6 inhibitor (options A and D) has limited supporting evidence after progression on a prior CDK4/6 inhibitor. Alpelisib + fulvestrant (option C) requires a PIK3CA mutation — DS has no actionable mutations. Ribociclib + tamoxifen (option D) is also incorrect — this combination carries a QTc prolongation risk and CDK4/6 inhibitor cross-resistance is expected after palbociclib failure.
[/expand]DS is treated with abemaciclib + letrozole for 2 years and then progresses. No actionable mutations found. Which is the most appropriate second-line treatment for DS?
A. Palbociclib + letrozole
B. Everolimus + exemestane
C. Alpelisib + fulvestrant
D. Ribociclib + tamoxifen
Explanation: After progression on CDK4/6 inhibitor + AI without actionable mutations, everolimus + exemestane (based on BOLERO-2) is the standard second-line option. Switching to another CDK4/6 inhibitor (palbociclib, ribociclib — options A and D) has no established benefit after prior CDK4/6 inhibitor progression; ribociclib + tamoxifen is additionally contraindicated due to QTc prolongation risk. Alpelisib + fulvestrant (option C) requires PIK3CA mutation — not present here.
[/expand]HZ is a 47-year-old postmenopausal woman with ER+/PR−/HER2− stage IA breast cancer treated with breast-conserving surgery + radiation + anastrozole. After 18 months of anastrozole, she develops bone metastases. The metastatic lesion is ER+, HER2−, PIK3CA-mutated, and BRCA-negative. What is the most appropriate option to treat HZ's metastatic breast cancer?
A. Alpelisib and fulvestrant
B. Everolimus
C. Doxorubicin and cyclophosphamide (AC)
D. Olaparib
Explanation: HZ has HR+/HER2−, PIK3CA-mutated metastatic breast cancer that progressed on adjuvant anastrozole (an aromatase inhibitor) — meeting the criteria for alpelisib + fulvestrant (SOLAR-1 trial, Category 1 recommendation). Alpelisib is a PI3Kα inhibitor approved specifically in combination with fulvestrant for postmenopausal HR+/HER2−/PIK3CA-mutated metastatic breast cancer progressing on or after endocrine therapy. Everolimus as monotherapy (option B) is not approved — it must be combined with exemestane. AC chemotherapy (option C) could be considered eventually but is not the first choice when a targeted option exists. Olaparib (option D) requires germline BRCA mutation — HZ is BRCA-negative.
[/expand]AH is a 50-year-old postmenopausal woman receiving adjuvant letrozole × 5 years for ER+/PR+/HER2− stage IA breast cancer. Her baseline DXA scan shows a T-score of −2.7. She is already taking calcium 1,500 mg PO daily and vitamin D3 800 IU PO daily. Which of the following is the most appropriate additional action based on her DXA scan?
A. Initiate denosumab every 6 months
B. Observation
C. Increase calcium and vitamin D supplementation
D. Initiate zoledronic acid every 4 weeks
Explanation: AH has osteoporosis (T-score −2.7) at baseline and is receiving an AI (letrozole), which is known to cause progressive bone loss. A bone-modifying agent (BMA) is indicated. Acceptable options include denosumab 60 mg SQ every 6 months, zoledronic acid (Reclast) 5 mg IV annually, or zoledronic acid 4 mg IV every 6 months. DXA should be repeated every 2 years. Observation (option B) is incorrect — AH has osteoporosis plus AI-induced bone loss risk. Increasing calcium and vitamin D (option C) is incorrect — she is already on appropriate supplementation doses. Zoledronic acid every 4 weeks (option D) is the dosing for bone metastases, not for osteoporosis/bone loss prevention in early-stage disease.
[/expand]FR is a 37-year-old premenopausal woman with bone-only metastases from ER+/PR+/HER2+ breast cancer who progressed on tamoxifen. She received THP × 6 cycles with good response and now plans to restart endocrine therapy. Her estradiol and FSH levels confirm premenopausal status. What is the most appropriate endocrine treatment for FR's metastatic disease?
A. Continue tamoxifen
B. Discontinue tamoxifen; start exemestane
C. Continue tamoxifen; add fulvestrant
D. Discontinue tamoxifen; start goserelin and anastrozole
Explanation: FR's breast cancer recurred while receiving tamoxifen — endocrine therapy must be changed. She is premenopausal, so AIs cannot be used alone; they require OAS (goserelin) to eliminate ovarian estrogen production. The appropriate approach is to discontinue tamoxifen and initiate OAS (goserelin) + AI (anastrozole) — this provides treatment equivalent to AI therapy in postmenopausal women. Continuing tamoxifen (option A) is incorrect — disease progressed on tamoxifen. Exemestane alone (option B) is incorrect — she is premenopausal and AIs cannot be used without OAS. Tamoxifen + fulvestrant (option C) is not a recommended combination per ASCO or NCCN guidelines.
[/expand]YC is a 37-year-old premenopausal woman with stage IA (T1c, N0, M0) TNBC who had a modified radical mastectomy with negative nodes and negative margins. She is planned to receive adjuvant dose-dense AC → weekly paclitaxel in 3 weeks. She is interested in fertility preservation. Which fertility preservation option is most appropriate for YC at this time?
A. Ovarian transposition
B. Embryo cryopreservation
C. Ovarian tissue cryopreservation
D. Leuprolide
Explanation: YC should be referred to a fertility specialist as soon as possible — BEFORE starting chemotherapy. Per ASCO guidelines, embryo cryopreservation and cryopreservation of unfertilized oocytes are the established, non-investigational options for fertility preservation in women facing chemotherapy. Ovarian transposition (option A) is only recommended for patients undergoing pelvic or abdominal radiation — not relevant here. Ovarian tissue cryopreservation (option C) is considered investigational and is not routinely recommended. Leuprolide/LHRH agonists (option D) — while studied in the POEMS trial — are still considered investigational by ASCO guidelines for fertility preservation; they are not the standard recommended option.
[/expand]FR has bone metastases from metastatic breast cancer and is receiving endocrine therapy. Her CrCl is within normal limits. Which regimen is most appropriate to prevent skeletal-related events (SREs)?
A. Denosumab 60 mg SQ every 6 months
B. Pamidronate 90 mg IV every 6 months
C. Zoledronic acid 4 mg IV every 12 weeks
D. Denosumab 120 mg SQ every 12 weeks
Explanation:
- For prevention of skeletal-related events in patients with bone metastases, both zoledronic acid 4 mg IV every 3–4 weeks (or every 12 weeks per recent evidence) and denosumab 120 mg SQ every 4 weeks are the standard options per ASCO and NCCN guidelines. Denosumab 60 mg SQ every 6 months (option A) is for osteopenia/osteoporosis prevention — NOT for bone metastases.
- Pamidronate every 6 months (option B) is incorrect — pamidronate should be given every 3–4 weeks for bone metastases.
- Denosumab every 12 weeks (option D) is incorrect — denosumab for bone metastases is given every 4 WEEKS, not every 12 weeks.
DS is a 45-year-old premenopausal woman with metastatic HR+/HER2− breast cancer treated with abemaciclib + letrozole + goserelin for 2.5 years, then progressed. Pathology shows PIK3CA mutation positive.Which second-line endocrine treatment is most appropriate for DS?
A. Palbociclib + fulvestrant + goserelin
B. Palbociclib + tamoxifen
C. Alpelisib + fulvestrant + goserelin
D. Alpelisib + tamoxifen
Answer: C. Alpelisib + fulvestrant + goserelin
Explanation: DS has PIK3CA-mutated HR+/HER2− metastatic breast cancer progressing after CDK4/6 inhibitor + AI. Alpelisib + fulvestrant is a Category 1 second-line recommendation per NCCN (SOLAR-1 trial). Because DS is premenopausal, goserelin must be added to provide OAS and eliminate ovarian estrogen — making option C the complete correct answer. Switching to another CDK4/6 inhibitor (options A and B) has limited evidence after prior CDK4/6 inhibitor failure. Alpelisib + tamoxifen (option D) is not a recommended combination — alpelisib is only approved with fulvestrant.
[/expand]The following questions are integrated clinical pharmacology cases. For each, select the single best answer.
P.S. is a 69-year-old woman with NYHA class II heart failure, CAD, and hypertension. She has T2N1M0 TNBC requiring adjuvant chemotherapy in addition to mastectomy and radiation.
Which chemotherapy option is best for P.S. at this time?
A. Doxorubicin and cyclophosphamide (AC) × 4 → paclitaxel × 4
B. Cyclophosphamide, methotrexate, and fluorouracil (CMF) × 6
C. Docetaxel, doxorubicin, and cyclophosphamide (TAC) × 6
D. Docetaxel + cyclophosphamide (TC) × 4
Explanation: P.S. has heart failure and CAD — anthracyclines (doxorubicin) are relatively contraindicated due to dose-dependent cardiotoxicity that would significantly worsen her cardiac status. TC (docetaxel + cyclophosphamide) is an anthracycline-free regimen with comparable efficacy for early-stage breast cancer and is the safest choice for her given her cardiac comorbidities. AC → paclitaxel (option A) and TAC (option C) both contain doxorubicin — contraindicated with significant pre-existing cardiac disease. CMF (option B) is an older regimen not considered a preferred NCCN option.
[/expand]J.W. is a 64-year-old postmenopausal woman with stage IIA breast cancer, history of DVT, and osteopenia (T-score = −1). Which endocrine option is best for J.W.?
A. Tamoxifen × 5 years
B. Tamoxifen × 2 years followed by letrozole × 3 years
C. Anastrozole × 5 years
D. Goserelin × 2 years followed by anastrozole × 3 years
Explanation: J.W. is postmenopausal — AIs are the preferred adjuvant endocrine therapy. Her history of DVT is an important consideration: tamoxifen significantly increases VTE risk and is relatively contraindicated in patients with prior DVT or PE. Anastrozole (AI) does NOT increase VTE risk and is the safer choice. Her osteopenia (T-score −1) is mild and manageable with calcium, vitamin D, and bone monitoring — not a contraindication to AI use. Goserelin (option D) is only for premenopausal women — J.W. is postmenopausal.
[/expand]T.T. is a 56-year-old perimenopausal woman with T3N2M0, HR+/HER2− poorly differentiated breast cancer. She is treated with mastectomy and radiation. Which systemic treatment approach is best for T.T. at this time?
A. AC × 4 → paclitaxel × 4
B. Cyclophosphamide, epirubicin, and fluorouracil × 6
C. TC × 4
D. CMF × 6
Explanation: T.T. has high-risk, locally advanced (T3N2M0) poorly differentiated HR+ breast cancer — intensive anthracycline + taxane-based chemotherapy is appropriate. AC → paclitaxel (dose-dense or conventional) is a preferred NCCN regimen for high-risk early-stage breast cancer. CEF/FEC (option B) is an older anthracycline-based regimen — reasonable but not the preferred modern option. TC (option C) is appropriate for lower-risk settings but less preferred for T3N2 high-risk disease where a taxane phase adds benefit. CMF (option D) is not a preferred NCCN regimen for high-risk disease.
[/expand]T.T. elects to receive adjuvant endocrine therapy. She is perimenopausal. Which endocrine agent regimen is the best option for her at this time?
A. Letrozole × 5 years followed by tamoxifen × 5 years
B. Letrozole × 3 years followed by tamoxifen × 2 years
C. Tamoxifen × 2 years followed by anastrozole × 3 years
D. Tamoxifen × 5 years followed by anastrozole × 5 years
Explanation: T.T. is perimenopausal — her menopausal status must guide therapy. For perimenopausal women, tamoxifen is initiated first. If she becomes postmenopausal after 5 years of tamoxifen, switching to an AI (anastrozole) for an additional 5 years is appropriate — this sequential strategy is guideline-supported. Starting with an AI alone (options A and B) is incorrect if menopausal status is not confirmed — AIs are only effective in postmenopausal women and could actually stimulate ovarian estrogen production in perimenopausal women. Option C (tamoxifen → AI over only 5 total years) is a valid shorter sequential option but option D (10 total years) is preferred for high-risk disease.
[/expand]J.S. is a 65-year-old postmenopausal woman with T1N0M0 HR+ breast cancer, history of mastectomy + radiation + CMF. She has hypertension, COPD, osteopenia (T-score = −1), and protein S deficiency. She will now receive adjuvant endocrine therapy. Which is the best approach for J.S. considering her osteopenia?
A. Anastrozole + calcium and vitamin D supplementation
B. Tamoxifen + calcium and vitamin D supplementation
C. Tamoxifen + zoledronic acid 4 mg IV every 6 months
D. Letrozole + zoledronic acid 4 mg IV every 6 months
The correct answer is A. Anastrozole + calcium and vitamin D supplementation.
Rationale
- Endocrine Selection: For a postmenopausal woman (age 65), an aromatase inhibitor (AI) like anastrozole is the guideline-preferred adjuvant endocrine therapy.
- Tamoxifen Contraindication: Options B and C are incorrect because J.S. has protein S deficiency, an inherited clotting trait. Tamoxifen is strictly contraindicated in patients with known inherited clotting traits or a history of VTE due to an increased risk of thromboembolic events.
- Bone Health Management: While AIs are associated with bone loss, J.S.'s T-score of -1.0 indicates only mild osteopenia. According to the treatment algorithms for patients starting an AI, those with a T-score between -1 and -1.5 should receive calcium and vitamin D supplementation and a repeat DXA scan in 2 years.
- Threshold for Bisphosphonates: Option D is incorrect because pharmacologic therapy with agents like zoledronic acid is typically reserved for those with a higher risk of fracture, specifically a T-score < -2.0.
P.C. is a 69-year-old postmenopausal woman with stage IIB HR+ breast cancer, history of mastectomy + adjuvant chemo. She has hypertension, diabetes mellitus, fibromyalgia, and rheumatoid arthritis. She will begin adjuvant endocrine therapy and is concerned about side effects affecting her conditions. Which endocrine option is best for P.C.?
A. Anastrozole 1 mg/day
B. Goserelin 3.6 mg SQ every 28 days
C. Tamoxifen 20 mg/day
D. Letrozole 2.5 mg/day
Explanation: P.C. has fibromyalgia and rheumatoid arthritis — aromatase inhibitors are well known to cause significant arthralgias and joint pain (musculoskeletal side effects), which would worsen her existing pain conditions. Tamoxifen does not cause the same degree of musculoskeletal toxicity as AIs and is the most appropriate choice given her comorbidities. Anastrozole and letrozole (options A and D) both cause arthralgias that would aggravate her fibromyalgia and rheumatoid arthritis. Goserelin (option B) is OAS — only for premenopausal women; P.C. is postmenopausal.
[/expand]A.J.B. is a 70-year-old postmenopausal woman who has been receiving tamoxifen for 4 months for stage IIB HR+/HER2− breast cancer. She is now diagnosed with pulmonary embolism and DVT and is initiated on heparin and warfarin. Which approach is best for A.J.B.'s breast cancer therapy?
A. Discontinue tamoxifen and begin exemestane 25 mg/day
B. Decrease tamoxifen to 10 mg/day and increase INR target to 3.5
C. Discontinue tamoxifen and begin anastrozole 1 mg/day
D. Continue tamoxifen 20 mg/day but increase INR target to 3.5
Explanation: Tamoxifen is a major risk factor for VTE — it must be DISCONTINUED when a patient develops PE or DVT. Switching to an aromatase inhibitor (anastrozole or exemestane) eliminates the VTE risk from tamoxifen while continuing effective endocrine therapy for her postmenopausal HR+ breast cancer. Both anastrozole (option C) and exemestane (option A) are reasonable — however, nonsteroidal AIs (anastrozole, letrozole) are generally used first-line. Reducing tamoxifen dose (option B) or continuing it (option D) in the setting of an acute PE is inappropriate — the drug must be stopped.
[/expand]B.S. is a 57-year-old woman on tamoxifen 20 mg/day for 2 years after breast cancer treatment. She recently started paroxetine for mood. Which concern is most important for the pharmacist to discuss with the oncologist?
A. Menopausal status
B. Treatment of her mood
C. Vaginal symptoms
D. Bone mineral density
Explanation: The critical pharmacist intervention here is the drug-drug interaction between paroxetine and tamoxifen. Paroxetine is a STRONG CYP2D6 inhibitor — tamoxifen requires CYP2D6 for conversion to its active metabolite endoxifen. Strong CYP2D6 inhibitors (paroxetine, fluoxetine) significantly reduce tamoxifen efficacy by preventing activation, potentially negating the breast cancer treatment benefit. The oncologist must be alerted immediately. Alternative antidepressants with minimal CYP2D6 inhibition — such as venlafaxine, citalopram, or escitalopram — should be used instead. The other options (A, C, D) are important monitoring points but none carries the same immediate pharmacokinetic interaction risk as the paroxetine-tamoxifen interaction.
[/expand]H.C. is a 45-year-old woman with a history of T1N1M0 breast cancer treated with mastectomy, radiation, and tamoxifen (on tamoxifen for 4 years). She presents with bloody vaginal discharge. Which condition is of most concern regarding H.C.'s vaginal discharge?
A. Tamoxifen
B. Perimenopause
C. Infection
D. Endometrial cancer
Explanation: Tamoxifen is a known risk factor for endometrial cancer due to its partial estrogen agonist effect on the uterine endometrium. Bloody vaginal discharge in a patient on tamoxifen must be evaluated urgently for endometrial pathology — endometrial cancer is the most serious and clinically concerning etiology and must be ruled out first. While tamoxifen itself (option A) causes vaginal discharge, this is the underlying pharmacologic mechanism — the clinical concern requiring immediate workup is endometrial cancer. Perimenopause (option B) and infection (option C) are lower-acuity differential diagnoses that should be considered after ruling out malignancy.
[/expand]P.N. is a 67-year-old postmenopausal woman with T2N1M0 ER+/PR+/HER2+ breast cancer, history of congestive heart failure and diabetes. She will receive surgery, radiation, and endocrine therapy. Which adjuvant systemic option is most appropriate for P.N.?
A. Fluorouracil, doxorubicin, and cyclophosphamide × 6 → trastuzumab
B. TAC × 4 with concurrent trastuzumab
C. CMF × 6 → trastuzumab
D. Docetaxel and carboplatin with concurrent trastuzumab (TC + H)
Explanation: P.N. has HER2+ breast cancer requiring HER2-targeted therapy. She has pre-existing congestive heart failure — anthracycline-containing regimens (FAC, TAC — options A, B) significantly increase cardiotoxicity risk with concurrent or sequential trastuzumab, and are contraindicated in patients with reduced cardiac function. The anthracycline-free regimen TCH (docetaxel + carboplatin + trastuzumab) is the safest HER2-directed chemotherapy approach for patients with pre-existing cardiac disease. CMF alone → trastuzumab (option C) omits the taxane component and is not a preferred regimen. Trastuzumab must NEVER be given concurrently with anthracyclines.
[/expand]S.R. is a 62-year-old woman who recently completed AC × 4 and is now receiving sequential paclitaxel. After two paclitaxel doses, she presents with painful numbness and tingling in her hands and feet. Which is the best approach to manage S.R.'s symptoms?
A. Ibuprofen 600 mg PO three times daily
B. Transdermal fentanyl 25-mcg patch every 3 days
C. Oxycodone 5 mg PO every 4 hours PRN
D. Acetaminophen 500 mg PO twice daily
Answer: D. Acetaminophen 500 mg PO twice daily
(Note: The best first-line pharmacologic approach for mild chemotherapy-induced peripheral neuropathy from paclitaxel includes analgesics for neuropathic pain. For mild symptoms, acetaminophen is the safest first option. For moderate-severe neuropathic pain, duloxetine is the preferred evidence-based option per ASCO guidelines, though it is not listed here. Among the options provided, acetaminophen is the most appropriate initial approach for mild symptoms without renal/hepatic concerns. Ibuprofen — option A — is an NSAID that provides anti-inflammatory benefit but carries GI/renal risks and is not the first-line for neuropathy. Options B and C — opioids — are reserved for severe, refractory neuropathic pain not controlled by first-line agents.)
[/expand]C.O. is an 82-year-old woman with T1N0M0 HR+/HER2− well-differentiated breast cancer. She has heart failure, pulmonary embolism history, depression, and poor performance status. She seeks treatment. Which is the best primary treatment option for C.O.?
A. Mastectomy → radiation → AC → paclitaxel → anastrozole × 5 years
B. Tamoxifen × 4 months → lumpectomy and radiation
C. Mastectomy → radiation + CMF × 6 → tamoxifen × 5 years
D. Mastectomy → radiation → anastrozole × 5 years
The best primary treatment option for C.O. is D. Mastectomy → radiation → anastrozole × 5 years.
Rationale
- Avoidance of Tamoxifen (Options B and C): Tamoxifen is strictly contraindicated in this patient because she has a history of pulmonary embolism. Both tamoxifen and raloxifene increase the risk of venous thromboembolism (VTE).
- Avoidance of AC Chemotherapy (Option A): Anthracyclines like doxorubicin (in the AC regimen) are associated with cumulative, dose-related cardiotoxicity and are generally avoided in patients with pre-existing heart failure.
- Tumor Biology: For a T1N0M0, well-differentiated (Grade 1) tumor, the benefit of adjuvant chemotherapy is minimal. Guidelines recommend endocrine monotherapy for small, low-grade, node-negative tumors.
- Preferred Endocrine Agent: An aromatase inhibitor (AI) like anastrozole is the preferred endocrine therapy for postmenopausal women and does not carry the VTE risks associated with tamoxifen.
J.J. is an African American woman with newly diagnosed HR−/PR 2%/HER2− invasive ductal carcinoma and two small liver lesions (0.7 cm and 1.1 cm) on CT. She has significant abdominal pain affecting ADLs and cannot sleep. Which is the best treatment for J.J. at this time?
A. Hormonal therapy
B. Single-agent chemotherapy
C. Combined chemotherapy and biologic therapy
D. Combination chemotherapy
Explanation: J.J. has ER-negative (PR 2% considered functionally negative per most guidelines), HER2-negative metastatic breast cancer with symptomatic visceral (liver) metastases — essentially metastatic TNBC. Hormonal therapy (option A) is not appropriate for ER-negative disease. Biologic therapy (option C) — trastuzumab or HER2-targeted — is not indicated for HER2-negative disease. Single-agent chemotherapy (option B) may be appropriate for asymptomatic low-burden metastatic disease, but J.J. has symptomatic visceral metastases affecting her daily activities — combination chemotherapy provides higher response rates and faster tumor control for symptom relief.
[/expand]G.T. is a 62-year-old woman with ER 70%/PR 65%/HER2− breast cancer who completed 5 years of adjuvant tamoxifen 15 years ago. She now has bone metastases (MBC). In addition to bisphosphonate therapy, which regimen is best for G.T.?
A. Anastrozole daily
B. Paclitaxel weekly
C. Tamoxifen daily
D. Capecitabine twice daily
Answer: A. Anastrozole daily
Explanation: G.T. has HR+ metastatic breast cancer. Since she completed tamoxifen 15 years ago (not currently on endocrine therapy) and has bone-only metastases (asymptomatic/slow-growing), endocrine therapy is appropriate before chemotherapy. Anastrozole (AI) is the preferred first-line endocrine therapy for postmenopausal HR+ metastatic disease. Tamoxifen (option C) could be used, but AI therapy is preferred for postmenopausal patients. Paclitaxel and capecitabine (options B and D) are chemotherapy options used when endocrine therapy fails or for visceral crisis — not appropriate as first-line for bone-only metastatic disease in an endocrine-naive patient.
[/expand]G.T. progressed on anastrozole (new femur and rib metastases) after 1 year. She is on bisphosphonate therapy. Which regimen is best for G.T. at this time?
A. Fulvestrant
B. Exemestane
C. Tamoxifen
D. Letrozole
Explanation: After progression on a nonsteroidal AI (anastrozole), the next endocrine option for postmenopausal HR+ metastatic breast cancer includes fulvestrant (estrogen receptor antagonist/degrader) or exemestane (steroidal AI) ± everolimus. Fulvestrant is an appropriate sequential endocrine option after AI failure. Exemestane (option B) is a steroidal AI — can be used alone or preferably with everolimus after nonsteroidal AI failure (BOLERO-2 data). Tamoxifen (option C) may be considered but is less preferred in postmenopausal patients. Letrozole (option D) is another nonsteroidal AI — cross-resistance after anastrozole failure makes switching to another nonsteroidal AI generally ineffective.
[/expand]M.D. is a 64-year-old woman with ER+/PR+/HER2− MBC who progressed on anastrozole then exemestane. She now has liver and bone metastases with elevated CA27.29. In addition to bisphosphonate therapy, which therapy is best for M.D.?
A. Fluoxymesterone 10 mg PO twice daily
B. Ethinyl estradiol 3 mg/day PO
C. Fulvestrant 250 mg IM once monthly
D. Megestrol acetate 160 mg PO in divided doses daily
Answer: C. Fulvestrant 250 mg IM once monthly
Explanation: M.D. has progressed through two AIs (anastrozole, then exemestane) — the next appropriate endocrine option is fulvestrant, an ER antagonist/degrader that works through a different mechanism than AIs. Note that current standard fulvestrant dosing is 500 mg IM on days 1, 15, and 29, then every 28 days (not 250 mg as stated) — but among the options provided, fulvestrant is the most guideline-appropriate choice. Fluoxymesterone (androgen) and ethinyl estradiol (high-dose estrogen) are very rarely used, older hormonal options not currently in standard guidelines. Megestrol acetate (progestin) is a third-line hormonal option with significant side effects (weight gain, thromboembolic risk) — less preferred than fulvestrant.
[/expand]Which should be prescribed to help prevent toxicity associated with bisphosphonate therapy?
A. Monitoring of serum calcium and creatinine
B. Tooth extractions after thorough discussion with dentist and oncologist
C. Avoidance of endodontic and restorative dental procedures
D. Prophylactic antibiotics
Explanation: Bisphosphonate therapy (particularly zoledronic acid) requires regular monitoring of renal function (serum creatinine) since nephrotoxicity is a key toxicity requiring dose adjustments, and electrolytes including calcium and phosphate. Dental procedures: the concern with bisphosphonates is osteonecrosis of the jaw (ONJ) — routine endodontic (root canal) and restorative (fillings, crowns) dental procedures CAN and SHOULD be performed normally. Option B is incorrect — tooth extractions should be AVOIDED or deferred if possible; if absolutely necessary, they require careful planning with the dental team. Option C is incorrect — avoidance of routine dental procedures is unnecessary and harmful to oral health. Prophylactic antibiotics (option D) are not routinely prescribed for bisphosphonate therapy.
[/expand]C.F. is a 42-year-old premenopausal woman with ER−/PR−/HER2− metastatic breast cancer (lung nodules) causing dyspnea limiting her ADLs. She previously received FAC × 4 → weekly paclitaxel × 12 weeks (adjuvant), then recurred with pulmonary metastases. Which therapy is best for C.F. at this time?
A. Docetaxel + capecitabine
B. Goserelin + anastrozole
C. Liposomal doxorubicin + vinorelbine
D. Goserelin + tamoxifen
Explanation: C.F. has TNBC (ER−/PR−/HER2−) with symptomatic pulmonary metastases limiting her ADLs — chemotherapy is the only systemic option. She previously received anthracycline (FAC) and taxane (paclitaxel) — combination non-anthracycline, non-taxane chemotherapy or sequential single agents are appropriate. Docetaxel + capecitabine is an established combination for metastatic breast cancer with demonstrated superiority over docetaxel alone. Options B and D containing goserelin + endocrine therapy are completely inappropriate — TNBC has no hormone receptors and does not respond to endocrine therapy. Liposomal doxorubicin + vinorelbine (option C) could be considered but docetaxel + capecitabine has stronger evidence.
[/expand]N.W. is a 64-year-old postmenopausal woman with ER−/PR−/HER2+ (by FISH) metastatic liver metastasis. She recalls receiving "red" chemotherapy (likely anthracycline) previously. Which is the best first-line treatment for N.W.'s HER2+ MBC?
A. Capecitabine + lapatinib
B. Trastuzumab + paclitaxel
C. Trastuzumab + liposomal doxorubicin
D. Trastuzumab monotherapy
Answer: B. Trastuzumab + paclitaxel
Explanation: N.W. has HER2+/HR− metastatic breast cancer. The current standard first-line is trastuzumab + pertuzumab + taxane (THP). Among the options provided, trastuzumab + paclitaxel is the most appropriate — it includes HER2-targeted therapy with a taxane backbone. Trastuzumab + liposomal doxorubicin (option C) — anthracyclines should NOT be given concurrently with trastuzumab due to cardiotoxicity. N.W. also previously received anthracycline. Trastuzumab monotherapy (option D) provides lower response rates without chemotherapy for HR-negative disease. Capecitabine + lapatinib (option A) is a later-line option for HER2+ MBC.
[/expand]N.W. had stable disease for 15 months on trastuzumab + paclitaxel. She now presents with new liver lesions (progression). Which regimen is best for N.W. at this time?
A. Capecitabine + lapatinib
B. Trastuzumab monotherapy
C. Liposomal doxorubicin
D. Gemcitabine + paclitaxel
Explanation: After progression on trastuzumab-based first-line therapy, the modern preferred second-line option is T-DXd (fam-trastuzumab deruxtecan). However, since that option is not listed, capecitabine + lapatinib is a well-established second-line HER2+ option with proven efficacy (EGF100151 trial). It targets HER2 through a different mechanism (lapatinib is a TKI) and has activity after trastuzumab failure. Trastuzumab monotherapy (option B) would provide less benefit than a combination including lapatinib. Liposomal doxorubicin (option C) and gemcitabine + paclitaxel (option D) are non-HER2-specific chemotherapy options — continuing HER2-directed therapy at progression is supported by clinical evidence showing benefit from maintaining HER2 targeting.
[/expand]14. The Breast Cancer Prevention Trial called the Study of Tamoxifen and Raloxifene (STAR) achieved similar breast cancer prevention in each arm. What adverse effects occurred significantly more with tamoxifen vs. raloxifene?
- A. Endometrial cancer, arthralgias, venous thromboembolism (VTE)
- B. Hot flashes, VTE, endometrial cancer
- C. Arthralgias, hot flashes, vomiting
- D. VTE, endometrial cancer, cataracts
- Tamoxifen (Nolvadex) and raloxifene (Evista) are both selective estrogen receptor modulators (SERMs).
- Tamoxifen is primarily used to treat breast cancer, whereas raloxifene is used for both osteoporosis and some breast cancer.
44. Which of the following is NOT an aromatase inhibitor used in estrogen receptor positive breast cancer?
- A. Anastrazole (Arimidex)
- B. Exemestane (Aromasin)
- C. Letrozole (Femara)
- D. Toremifene (Fareston)
- The first three answer choices are all aromatase inhibitors.
- Anastrozole and letrozole are both selective, nonsteroidal, competitive aromatase inhibitors, while exemestane is a steroidal aromatase inhibitor that binds irreversibly to the enzyme.
- On the other hand, toremifene is a selective estrogen receptor modulator similar to tamoxifen.
69. All of the following are selective estrogen receptor modulators (SERM) EXPECTE:
- A Raloxifene (Evista) (8%)
- B Tamoxifen (Nolvadex) (11%)
- C Toremifene (Fareston) (18%)
- D Exemestane (Aromasin) (63%)
- The first three answer options are all selective estrogen receptor modulators.
- Tamoxifen possesses antiestrogen effects on certain tissues such as the breast, vaginal mucosa, and estrogenic effects on the bones, lipids, and endometrium. Tamoxifen has also been associated with a hypolipidemic effect.
- Toremifene is similar to tamoxifen.
- However, raloxifene is a selective estrogen receptor down regulator and does not exhibit agonistic activity on the endometrium, the mechanism which leads to the increased risk of endometrial cancers associated with tamoxifen.
- Exemestane is a steroidal aromatase inhibitor that binds irreversibly to the enzyme.
100. FJ is a 44-year-old metastatic breast cancer patient with stage 3 chronic kidney disease (creatinine clearance approximately 40 mL/min). Which of the following breast cancer agents are primarily cleared by the kidneys and requires a dosage adjustment in FJ?
- A. Capecitabine (Xeloda), cisplatin (Platinol), and eribulin (Halaven)
- B. Docetaxel (Taxotere), mitoxantrone (Novantrone), carboplatin (Praphatin)
- C. Liposomal doxorubicin (Doxil), paclitaxel (Taxol), vinorelbine (Navelbine)
- D. Gemcitabine (Gemzar), ixabepilone (Ixempra), epirubicin (Eflence)
- Capecitabine, platinum agents (carboplatin and cisplatin), and eribulin are all agents used in metastatic breast cancer that require dosage adjustment in patients with a creatinine clearance < 50 mL/min.
- All the other agents are primarily cleared by the liver.
- Gemcitabine is cleared renally; however, there are no adjustments recommended for mild to severe renal disease.